What is the pathophysiology of microscopic polyangiitis (MPA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pathophysiology of Microscopic Polyangiitis

Microscopic polyangiitis (MPA) is an autoimmune small-vessel vasculitis driven primarily by anti-myeloperoxidase (MPO) ANCA antibodies that activate neutrophils, causing necrotizing inflammation of capillaries, venules, and arterioles without granuloma formation. 1, 2

Core Autoimmune Mechanism

The pathogenic cascade begins with autoantibody formation against myeloperoxidase (MPO), a neutrophil enzyme normally sequestered in primary granules. 1 The fundamental question in MPA pathogenesis is why the immune system develops antibodies against this self-antigen that is typically hidden from immune surveillance. 1

Autoantigen Exposure and Antibody Development

  • Defective neutrophil apoptosis or impaired clearance of apoptotic cell fragments leads to prolonged exposure of MPO to the immune system, breaking tolerance. 1

  • Infection may trigger disease through molecular mimicry, where microbial antigens structurally resemble MPO, initiating cross-reactive antibody production. 1

  • MPO becomes abnormally expressed on cell surfaces when complexed with HLA class II molecules (particularly HLA-DR), creating novel epitopes that are recognized by autoantibodies. 3

  • This MPO/HLA-DR complex presentation exposes cryptic autoantibody epitopes not normally accessible when MPO is properly sequestered intracellularly. 3

Neutrophil Activation and Vascular Injury

Once MPO-ANCA antibodies form, they bind to and activate primed neutrophils, triggering a destructive inflammatory cascade. 1, 4

Direct Neutrophil-Mediated Damage

  • ANCA binding to neutrophils causes release of oxygen radicals, lytic enzymes, and inflammatory cytokines that directly damage vessel walls. 1

  • MPO-ANCA can activate MPO enzymatically to generate hypochlorous acid (HOCl), a highly reactive oxidant species that causes severe endothelial cell damage. 4

  • This oxidative burst is specifically triggered by anti-MPO antibodies and can be blocked by antioxidants like N-acetylcysteine, confirming the pathogenic role of the antibodies. 4

  • Activated neutrophils degranulate at sites of tissue injury, releasing MPO that is then rapidly eliminated by specific inhibitors under normal circumstances. 1

Immune Complex Formation

  • ANCA may induce immune complex formation that deposits in vessel walls, though MPA is characterized by pauci-immune (few or no immune deposits) glomerulonephritis. 1, 2

  • The relative absence of immunoglobulin deposits distinguishes MPA from immune complex-mediated vasculitides like Henoch-Schönlein purpura. 5

Direct Endothelial Injury

  • ANCA can directly adhere to and kill endothelial cells, causing necrotizing vasculitis independent of neutrophil activation. 1

Vessel-Specific Pathology

MPA predominantly affects small vessels—capillaries, venules, and arterioles—though small and medium arteries may occasionally be involved. 2, 5

Histopathologic Features

  • Necrotizing vasculitis with fibrinoid necrosis of vessel walls is the hallmark finding, occurring without granulomatous inflammation. 2, 5

  • The absence of granulomas is the key distinguishing feature from granulomatosis with polyangiitis (GPA), as the vasculitis itself is pathologically identical. 5

  • Pauci-immune necrotizing and crescentic glomerulonephritis is the characteristic renal manifestation, reflecting capillary inflammation with minimal immune complex deposition. 2, 5

  • Pulmonary capillaritis with hemorrhagic alveolar damage occurs commonly, making MPA the most frequent cause of pulmonary-renal vasculitic syndrome. 2, 5

Clinical Implications of Pathophysiology

Understanding that MPA is primarily MPO-ANCA driven (in contrast to PR3-ANCA in GPA) has direct clinical relevance for diagnosis and monitoring. 1, 2

ANCA Serology Patterns

  • Approximately 70% of MPA patients have detectable MPO-ANCA (perinuclear pattern), though a subset remains ANCA-negative. 2, 4

  • The minority of MPA patients may have PR3-ANCA rather than MPO-ANCA, though MPO predominates. 2

  • ANCA-negative MPA exists and presents a diagnostic challenge, as the pathophysiology in these cases may involve alternative mechanisms not yet fully elucidated. 1

Age and Severity Correlation

  • Patients with MPA are typically older at presentation and have more severe kidney disease compared to GPA patients, reflecting the predilection for renal capillary involvement. 1

Common Pitfalls in Understanding MPA Pathophysiology

Do not confuse MPA with polyarteritis nodosa—MPA involves capillaries and venules while polyarteritis nodosa affects only medium-sized arteries without capillary involvement. 5

Do not assume all ANCA-associated vasculitis has the same pathophysiology—while MPA, GPA, and EGPA share ANCA positivity, their distinct clinical features reflect different underlying mechanisms (MPO vs PR3 antibodies, presence/absence of granulomas, eosinophil involvement). 1, 5

Recognize that the pathogenic role of MPO-ANCA is supported by both in vitro studies showing direct neutrophil activation and endothelial damage, and clinical evidence that B-cell depletion (rituximab) effectively treats disease by reducing antibody production. 1, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Microscopic polyangiitis (microscopic polyarteritis).

Seminars in diagnostic pathology, 2001

Related Questions

What are the diagnostic criteria for Microscopic Polyangiitis (MPA)?
What are the medical uses of GPA (Glycophorin A), EPA (Eicosapentaenoic acid), and MPA (Medroxyprogesterone acetate)?
Is maintenance treatment with Rituximab (rituximab) 500mg IV x1 medically necessary and appropriate for a patient with ANCA-associated vasculitis and Microscopic Polyangiitis (MPA)?
What is the recommended approach to myeloperoxidase (MPO) utilization in clinical practice?
What is the role of oral anticoagulants, such as warfarin or novel oral anticoagulants (NOACs) like rivaroxaban (Xarelto), apixaban (Eliquis), or dabigatran (Pradaxa), in managing medium vessel vasculitis, like polyarteritis nodosa (PAN), and small vessel vasculitis, such as granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)?
What are the next steps for an asthmatic patient experiencing a persistent cough and using albuterol (short-acting beta-agonist) 3-4 times per day?
What is the recommended dosing of Nabilone (cannabidiol) for a patient with a history of cancer and chemotherapy-induced nausea and vomiting, considering factors such as age, weight, and impaired renal function?
What is the best management approach for a patient with compensated cirrhosis (no history of ascites), presenting with peripheral edema and heel pain?
How do you differentiate between ischemic and hemorrhagic stroke on a computed tomography (CT) scan?
What are the considerations for using Slynd (drospirenone) for uterine protection with an estriol 0.05 patch in a peri- or post-menopausal woman?
How to manage a patient with a history of depression or anxiety, currently on Pristiq (desvenlafaxine), who is experiencing nocturnal urinary frequency and dysuria?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.